IN8bio

Our CEO and co-founder, William Ho, will co-chair, chair and present on Tuesday, March 25th at the 11th Annual Immuno-Oncology 360° Conference 2025. For more details read here: bit.ly/3XXuIO2 #IO360Summit #GDTcells

#NEWS: We are pleased to report our fourth-quarter and full-year 2024 financial results and recent business highlights. Read the press release for full details: bit.ly/43MCU7w #IN8bio #CancerZero #GDTCells

We are happy to announce that our CEO and Co-founder, William Ho, will present at Tribe Public's Webinar Presentation and Q&A Event titled "The DeltEx Platform: Advancing Innovative Immune Solutions for Cancer and Autoimmune Diseases." He will delve into IN8bio's CANCER ZERO mission and more! This event will take place Wednesday, March 12th, at 11 a.m. EST. Reserve your spot today! Register at https://lnkd.in/emcRBb8W.

IN8bio’s Senior Director of Analytical Development, Mariska ter Haak, will present data on our DeltEx γδ T Cell  Manufacturing platform at iRepitoire’s cell therapy webinar tomorrow at noon EST, titled “Evaluating Gene Expression and TCR Repertoire Dynamics in γδ T Cell Therapies." She will delve into the cellular and molecular characterization of our cellular therapy products, demonstrating the robust γδ T cell manufacturing technology developed at IN8bio. Registration: hubs.li/Q036wy5M0

After taking the necessary time to select the right candidate with a thought-out #clinical and #commercial strategy, IN8bio is ready to make its move into #autoimmunity. https://lnkd.in/dx653iBM #biotechnology #CART #celltherapy #clinicalresearch #corporateaffairs #genetherapy #immunology #leukemia #lupus #lymphomas #pharmaceuticals

Thanks FirstWord Pharma for speaking with William Ho, CEO & Founder at IN8bio: The biotech unveiled a gamma-delta T cell engager (TCE) platform on Monday, as well as the first candidate to be built with the new technology: INB-619, a CD19-targeted TCE that could help treat leukaemias, lymphomas, and yes, autoimmune diseases. "When everybody else moved with cellular therapy into the autoimmune space, we didn't do that," IN8bio CEO William Ho told FirstWord. "We took our time, used our knowledge about biology, used our knowledge about diseases and gamma-delta T-cell biology, to create something where we think we can have some real advantages." Read the article by Elizabeth Eaton: https://lnkd.in/ebAYSEFK

Yesterday we presented at the TD Cowen 45th Healthcare Conference. Excited to introduce our latest innovation—the INB-600 platform! Why does this matter? • T cell engagers (TCEs) have been one of the biggest success stories in immunotherapy, with companies like J&J and Roche building billion-dollar franchises around these therapies. • Despite the promise, gamma-delta T cell engagers have struggled—until now. • Our INB-619 preclinical candidate is designed to not only engage γδ T cells but also expand them, creating a more powerful, longer-lasting immune response for blood cancers and autoimmune diseases. • Unlike traditional CD3-based TCEs, which come with severe risks like cytokine release syndrome and neurotoxicity, our approach could offer a safer, more effective alternative. This is a game-changing moment for gamma-delta T cell therapies. Stay tuned for more updates as we continue to work on achieving our goal of #CancerZero!  #Biotech #Immunotherapy #CancerResearch #TcellEngagers #GDTcells

INB-600, our new advanced gamma-delta (γδ) T cell Engager (TCE) platform, broadly applies to oncology and autoimmune diseases and represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells while expanding γδ effector cells. INB-619, a next-generation γδ TCE targeting CD19, eradicates B cells in preclinical models, maintaining depletion over time as the γδ T cells expand in response to TCE stimulation. Read more: bit.ly/3EW6oFB. Watch a replay of today's company presentation at TD Cowen: bit.ly/in8bioevents. #CancerZero IN8bio

#NEWS: We are pleased to announce new data on our next-generation gamma-delta (γδ) T cell Engager (TCE) platform for oncology and autoimmune diseases – INB-600. INB-600 is a novel γδ T cell-based TCE platform designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This technology is designed to efficiently eliminate target cells while stimulating γδ T cell expansion to drive deeper and potentially longer-lasting immune responses. By leveraging our expertise in γδ T cell biology, we have developed a technology that combines exceptional preclinical potency while broadly expanding immune surveillance and potentially avoiding the dangerous side effects of existing approaches. Our CEO, William Ho, will discuss this platform and data today at 10:30 a.m. EST at the TD Cowen 45th Annual Health Care Conference. A webcast will also be available. Read more: bit.ly/3EW6oFB

We are happy to announce that William Ho, our CEO and co-founder, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 AM ET. Read the full release here: bit.ly/41t4V2p #CancerZero